BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 10068201)

  • 1. Genetic profile of the giant cell glioblastoma.
    Peraud A; Watanabe K; Schwechheimer K; Yonekawa Y; Kleihues P; Ohgaki H
    Lab Invest; 1999 Feb; 79(2):123-9. PubMed ID: 10068201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas.
    Tohma Y; Gratas C; Biernat W; Peraud A; Fukuda M; Yonekawa Y; Kleihues P; Ohgaki H
    J Neuropathol Exp Neurol; 1998 Jul; 57(7):684-9. PubMed ID: 9690672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic profile of gliosarcomas.
    Reis RM; Könü-Lebleblicioglu D; Lopes JM; Kleihues P; Ohgaki H
    Am J Pathol; 2000 Feb; 156(2):425-32. PubMed ID: 10666371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 mutations versus EGF receptor expression in giant cell glioblastomas.
    Peraud A; Watanabe K; Plate KH; Yonekawa Y; Kleihues P; Ohgaki H
    J Neuropathol Exp Neurol; 1997 Nov; 56(11):1236-41. PubMed ID: 9370234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q.
    Boström J; Cobbers JM; Wolter M; Tabatabai G; Weber RG; Lichter P; Collins VP; Reifenberger G
    Cancer Res; 1998 Jan; 58(1):29-33. PubMed ID: 9426052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational profile of the PTEN gene in primary human astrocytic tumors and cultivated xenografts.
    Schmidt EE; Ichimura K; Goike HM; Moshref A; Liu L; Collins VP
    J Neuropathol Exp Neurol; 1999 Nov; 58(11):1170-83. PubMed ID: 10560660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular pathogenesis of malignant gliomas.
    Rasheed BK; Wiltshire RN; Bigner SH; Bigner DD
    Curr Opin Oncol; 1999 May; 11(3):162-7. PubMed ID: 10328589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic pathways to glioblastoma: a population-based study.
    Ohgaki H; Dessen P; Jourde B; Horstmann S; Nishikawa T; Di Patre PL; Burkhard C; Schüler D; Probst-Hensch NM; Maiorka PC; Baeza N; Pisani P; Yonekawa Y; Yasargil MG; Lütolf UM; Kleihues P
    Cancer Res; 2004 Oct; 64(19):6892-9. PubMed ID: 15466178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter.
    Fujisawa H; Kurrer M; Reis RM; Yonekawa Y; Kleihues P; Ohgaki H
    Am J Pathol; 1999 Aug; 155(2):387-94. PubMed ID: 10433932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation among pathology, genotype, and patient outcomes in glioblastoma.
    Homma T; Fukushima T; Vaccarella S; Yonekawa Y; Di Patre PL; Franceschi S; Ohgaki H
    J Neuropathol Exp Neurol; 2006 Sep; 65(9):846-54. PubMed ID: 16957578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional evaluation of p53 and PTEN gene mutations in gliomas.
    Kato H; Kato S; Kumabe T; Sonoda Y; Yoshimoto T; Kato S; Han SY; Suzuki T; Shibata H; Kanamaru R; Ishioka C
    Clin Cancer Res; 2000 Oct; 6(10):3937-43. PubMed ID: 11051241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular genetics of radiographically defined de novo glioblastoma multiforme.
    Tortosa A; Ino Y; Odell N; Swilley S; Sasaki H; Louis DN; Henson JW
    Neuropathol Appl Neurobiol; 2000 Dec; 26(6):544-52. PubMed ID: 11123721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas.
    Sung T; Miller DC; Hayes RL; Alonso M; Yee H; Newcomb EW
    Brain Pathol; 2000 Apr; 10(2):249-59. PubMed ID: 10764044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PTEN mutations in gliomas and glioneuronal tumors.
    Duerr EM; Rollbrocker B; Hayashi Y; Peters N; Meyer-Puttlitz B; Louis DN; Schramm J; Wiestler OD; Parsons R; Eng C; von Deimling A
    Oncogene; 1998 Apr; 16(17):2259-64. PubMed ID: 9619835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 and PTEN gene mutations in gemistocytic astrocytomas.
    Watanabe K; Peraud A; Gratas C; Wakai S; Kleihues P; Ohgaki H
    Acta Neuropathol; 1998 Jun; 95(6):559-64. PubMed ID: 9650746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression.
    Nozaki M; Tada M; Kobayashi H; Zhang CL; Sawamura Y; Abe H; Ishii N; Van Meir EG
    Neuro Oncol; 1999 Apr; 1(2):124-37. PubMed ID: 11550308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic pathways to primary and secondary glioblastoma.
    Ohgaki H; Kleihues P
    Am J Pathol; 2007 May; 170(5):1445-53. PubMed ID: 17456751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors.
    Lang FF; Miller DC; Koslow M; Newcomb EW
    J Neurosurg; 1994 Sep; 81(3):427-36. PubMed ID: 8057151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines.
    Teng DH; Hu R; Lin H; Davis T; Iliev D; Frye C; Swedlund B; Hansen KL; Vinson VL; Gumpper KL; Ellis L; El-Naggar A; Frazier M; Jasser S; Langford LA; Lee J; Mills GB; Pershouse MA; Pollack RE; Tornos C; Troncoso P; Yung WK; Fujii G; Berson A; Steck PA
    Cancer Res; 1997 Dec; 57(23):5221-5. PubMed ID: 9393738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary and secondary glioblastomas: from concept to clinical diagnosis.
    Kleihues P; Ohgaki H
    Neuro Oncol; 1999 Jan; 1(1):44-51. PubMed ID: 11550301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.